文献速递血栓与止血

靶向因子XI和因子XIa预防血栓形成

Targeting factor XI and factor XIa to prevent thrombosis.
PubMed 文献 · Blood · 2024-01-01

直接口服抗凝药(DOACs)广泛替代华法林等维生素K拮抗剂用于长期抗凝,但因其靶向止血所需蛋白酶而增加严重出血风险。血浆酶原因子XI(FXI)及其蛋白酶形式因子XIa(FXIa)因实验室和流行病学证据支持其参与静脉和动脉血栓形成而成为有前景的药物靶点。2期研究显示,抑制FXI或FXIa的药物在全膝关节置换术后预防静脉血栓栓塞不劣于或优于低分子量肝素,且心脏病患者出血少于DOACs,3期试验已启动。

要点

  • DOACs靶向凝血酶或FXa,抗凝有效但增加严重出血风险,导致部分患者治疗不足。
  • 实验室和流行病学证据支持FXI参与静脉和动脉血栓形成,靶向FXI/FXIa预期出血风险低于华法林或DOACs。
  • 2期研究中FXI/FXIa抑制剂在全膝关节置换术后预防静脉血栓栓塞不劣于或优于低分子量肝素,心脏病患者出血少于DOACs。

核心结论

  • 基于70年对FXI缺乏患者的临床观察,预期靶向FXI/FXIa的药物所致出血比华法林或DOACs更轻。
  • 2期研究显示FXI/FXIa抑制剂在全膝关节置换术后预防静脉血栓栓塞不劣于或优于低分子量肝素,心脏病患者出血少于DOACs。
  • 基于早期结果,已启动比较FXI/FXIa靶向药物与标准治疗或安慰剂的3期试验。

研究设计与样本

  • 综述,总结FXI在正常和异常凝血中的作用及FXI/FXIa抑制剂的临床前、非临床和临床研究结果。

主要发现

  • 实验室和流行病学研究表明FXI参与静脉和动脉血栓形成。
  • 2期研究中,抑制FXI或FXIa的药物在全膝关节置换术后预防静脉血栓栓塞不劣于或优于低分子量肝素。
  • 心脏病患者使用FXI或FXIa抑制剂出血少于使用DOACs的患者。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Direct oral anticoagulants (DOACs) that inhibit the coagulation proteases thrombin or factor Xa (FXa) have replaced warfarin and other vitamin K antagonists (VKAs) for most indications requiring long-term anticoagulation. In many clinical situations, DOACs are as effective as VKAs, cause less bleeding, and do not require laboratory monitoring. However, because DOACs target proteases that are required for hemostasis, their use increases the risk of serious bleeding. Concerns over therapy-related bleeding undoubtedly contribute to undertreatment of many patients who would benefit from anticoagulation therapy. There is considerable interest in the plasma zymogen factor XI (FXI) and its protease form factor XIa (FXIa) as drug targets for treating and preventing thrombosis. Laboratory and epidemiologic studies support the conclusion that FXI contributes to venous and arterial thrombosis. Based on 70 years of clinical observations of patients lacking FXI, it is anticipated that drugs targeting this protein will cause less severe bleeding than warfarin or DOACs. In phase 2 studies, drugs that inhibit FXI or FXIa prevent venous thromboembolism after total knee arthroplasty as well as, or better than, low molecular weight heparin. Patients with heart disease on FXI or FXIa inhibitors experienced less bleeding than patients taking DOACs. Based on these early results, phase 3 trials have been initiated that compare drugs targeting FXI and FXIa to standard treatments or placebo. Here, we review the contributions of FXI to normal and abnormal coagulation and discuss results from preclinical, nonclinical, and clinical studies of FXI and FXIa inhibitors.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Gailani D, Gruber A. Targeting factor XI and factor XIa to prevent thrombosis. Blood. 2024. PMID: 38142404. doi:10.1182/blood.2023020722

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。